We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563349

CAS#: 1434047-61-6

Description: VMY-2-95 is a selective desensitizer of α4β2 nicotinic acetylcholine receptors (nAChRs).

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-08-11. Prices are subject to change without notice.

VMY-2-95 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 563349
Name: VMY-2-95
CAS#: 1434047-61-6
Chemical Formula: C17H16N2O
Exact Mass: 264.1263
Molecular Weight: 264.32
Elemental Analysis: C, 77.25; H, 6.10; N, 10.60; O, 6.05

Synonym: VMY-2-95; VMY 2 95; VMY295; VMY 295; VMY-295;

IUPAC/Chemical Name: 3-[(2S)-2-Azetidinylmethoxy]-5-(2-phenylethynyl)-pyridine


InChi Code: InChI=1S/C17H16N2O/c1-2-4-14(5-3-1)6-7-15-10-17(12-18-11-15)20-13-16-8-9-19-16/h1-5,10-12,16,19H,8-9,13H2/t16-/m0/s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Rezvani AH, Slade S, Wells C, Yenugonda VM, Liu Y, Brown ML, Xiao Y, Kellar KJ, Levin ED. Differential efficacies of the nicotinic α4β2 desensitizing agents in reducing nicotine self-administration in female rats. Psychopharmacology (Berl). 2017 Sep;234(17):2517-2523. doi: 10.1007/s00213-017-4641-6. Epub 2017 May 29. PubMed PMID: 28555315.

2: Kong H, Song JK, Yenugonda VM, Zhang L, Shuo T, Cheema AK, Kong Y, Du GH, Brown ML. Preclinical studies of the potent and selective nicotinic α4β2 receptor ligand VMY-2-95. Mol Pharm. 2015 Feb 2;12(2):393-402. doi: 10.1021/mp5003569. Epub 2015 Jan 20. PubMed PMID: 25533629; PubMed Central PMCID: PMC4319692.

3: Yenugonda VM, Xiao Y, Levin ED, Rezvani AH, Tran T, Al-Muhtasib N, Sahibzada N, Xie T, Wells C, Slade S, Johnson JE, Dakshanamurthy S, Kong HS, Tomita Y, Liu Y, Paige M, Kellar KJ, Brown ML. Design, synthesis and discovery of picomolar selective α4β2 nicotinic acetylcholine receptor ligands. J Med Chem. 2013 Nov 14;56(21):8404-21. doi: 10.1021/jm4008455. Epub 2013 Oct 18. PubMed PMID: 24047231.

4: Levin ED, Sexton HG, Gordon K, Gordon CJ, Xiao Y, Kellar KJ, Yenugonda VM, Liu Y, White MP, Paige M, Brown ML, Rezvani AH. Effects of the sazetidine-a family of compounds on the body temperature in wildtype, nicotinic receptor β2-/- and α7-/- mice. Eur J Pharmacol. 2013 Oct 15;718(1-3):167-72. doi: 10.1016/j.ejphar.2013.08.037. Epub 2013 Sep 12. PubMed PMID: 24036108; PubMed Central PMCID: PMC3844546.